亚洲一区在线观看尤物,在线不卡日本v二区%20https,国产成人精品日本亚洲专区6

Antibiotic SF 767 A

NMR下載 COA and HPLC MSDS下載
names：
Antibiotic SF 767 A
CAS號：
36441-41-5
MDL Number：
MF(分子式)： C29H55N5O18 MW(分子量)： 761.77
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	(2R,3S,4S,5S,6R)-2-(((2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3R,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-4-hydroxytetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
英文別名	Lividomycin; Antibiotic SF 767 A; SF 767 A; SF-767 A; SF767 A; Antibiotic 503-2; Lividomicina;
CAS號	36441-41-5
Inchi	InChI=1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24+,25-,26-,27-,28-,29+/m1/s1
InchiKey	DBLVDAUGBTYDFR-RRCSYQSCSA-N
分子式 Formula	C29H55N5O18
分子量 Molecular Weight	761.77
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Antibiotic SF 767 A(CAS:36441-41-5):僅限應(yīng)用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應(yīng)用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Antibiotic SF 767 A is an antibiotic.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]Clausnitzer D, Piepersberg W, Wehmeier UF. The oxidoreductases LivQ and NeoQ are responsible for the different 6'-modifications in the aminoglycosides lividomycin and neomycin. J Appl Microbiol. 2011 Sep;111(3):642-5[1]doi: 10.1111/j.1365-2672.2011.05082.x. Epub 2011 Jul 12. PubMed PMID: 21689223.

[2]Kobayashi F, Yamaguchi M, Mitsuhashi S. Activity of lividomycin against Pseudomonas aeruginosa: its inactivation by phosphorylation induced by resistant strains. Antimicrob Agents Chemother. 1972 Jan;1(1):17-21. PubMed PMID: 4207755; PubMed Central PMCID: PMC444159.

[3] Mori T, Kyotani Y, Watanabe I, Oda T. Chemical conversion of lividomycin A into lividomycin B. J Antibiot (Tokyo). 1972 Feb;25(2):149-50. PubMed PMID: 5034809.

[4] Yamaguchi M, Koshi T, Kobayashi F, Mitsuhashi S. Phosphorylation of lividomycin by Escherichia coli carrying an R factor. Antimicrob Agents Chemother. 1972 Sep;2(3):142-6. PubMed PMID: 4597704; PubMed Central PMCID: PMC444281.

[5] Kondo H, Miwa T, Suhachiro M, Yokouchi S, Ando Y. [Clinical experiences of lividomycin on respiratory tract infections (author's transl)]. Jpn J Antibiot. 1975 Apr;28(2):149-54. Japanese. PubMed PMID: 1041282.

6: Yamamoto H, Kondo S, Maeda K, Umezawa H. Synthesis of lividomycin A 5''-phosphate, an enzymatically inactivated lividomycin A. J Antibiot (Tokyo). 1972 Aug;25(8):485-6. PubMed PMID: 4648492.7: Takahashi R, Kato S. [Lividomycin therapy in intestinal infections with special reference to the combined use of lividomycin and AB-PC]. Kansenshogaku Zasshi. 1973 Aug;47(8):283-8. Japanese. PubMed PMID: 4202860.8: Kuntzmann F, Weiss JM, Berthel M, Colonna JC, Conraux C, Reinhardt W, Brogard JM, Federspil P. [Ototoxicity of aminoglucosides. A case of deafness after lividomycin]. Nouv Presse Med. 1979 Apr 28;8(19):1604-5. French. PubMed PMID: 258790.9: Yamaguchi M, Eda J, Kobayashi F, Mitsuhashi S. Mode of action of lividomycin on protein synthesis in Escherichia coli. Antimicrob Agents Chemother. 1973 Sep;4(3):380-2. PubMed PMID: 4586150; PubMed Central PMCID: PMC444562.10: Tsukamura M. A preliminary trial of lividomycin in patients with pulmonary tuberculosis. Tubercle. 1972 Mar;53(1):43-6. PubMed PMID: 5038199.1

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開